Autoantibodies against interleukin 1α in rheumatoid arthritis: Association with long term radiographic outcome

Annals of the Rheumatic Diseases

Volumn 61, Issue 7, 2002, Pages 598-602

  Graudal, N A ^a,d,e   Svenson, M ^a   Tarp, U ^b   Garred, P ^c   Jurik, A G ^b   Bendtzen, K ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1ALPHA; IODINE 125; RHEUMATOID FACTOR; INTERLEUKIN 1;

ADULT; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIOGRAPHY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SEROCONVERSION; SERUM; ADOLESCENT; AGED; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0035984101     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.7.598     Document Type: Article

References (47)

1. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
2. Biologic basis for interleukin-1 in disease
3. Cytokines in infectious diseases
4. Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention
5. High-avidity autoantibodies to cytokines
6. Interleukin-1-receptor antagonist. Role in biology
7. IL-1alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
8. Combined sib-TDT and TDT provide evidence for the linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis
9. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist deficient mice
10. In vivo administration with IL-1 accelerates the development of collagen induced arthritis in mice
11. Interleukin 1 enhances the development of spontaneous arthritis in MRL/lpr mice
12. Pro- and antiinflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats
13. Arthritis induced by continuous infusion of hr-interleukin-1 alpha into the rabbit knee joint
14. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis
15. Plasma levels of interleukin-1-alpha in rheumatoid arthritis
16. Peripheral blood and synovial fluid monocyte expression of interleukin 1 alpha and 1 beta during active rheumatoid arthritis
17. Interleukin-1-inhibitory IgG in sera from some patients with rheumatoid arthritis
18. IgG autoantibodies against interleukin 1 a in sera of normal individuals
19. Sex- and age dependency of IgG auto-antibodies against IL-1 a in healthy humans
20. Effects of human anti-IL-1 a autoantibodies on receptor binding and biological activities of IL-1
21. Generation and characteristics of a human monoclonal autoantibody that acts as a high affinity interleukin-1 a specific inhibitor
22. Natural and induced anticytokine antibodies in humans
23. Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects
24. High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: A follow-up study
25. Cytokine autoantibodies in rheumatoid arthritis
26. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF a, anti-IL-1 a/β, and IL-1 Ra
27. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
28. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
29. 1958 Revision of diagnostic criteria for rheumatoid arthritis
30. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films
31. Radiographic progression in rheumatoid arthritis. A long-term prospective study of 109 patients
32. Distribution and characterization of autoantibodies to interleukin 1 a in normal human sera
33. Interleukins and their receptors
34. Interleukin-1 gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis
35. Increased incidence of autoantibodies to interleukin 1 a in rheumatoid arthritis with interstitial lung disease
36. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factoralfa (cA2) versus placebo in rheumatoid arthritis
37. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF a treatment
38. Etanercept: Therapeutic use in patients with rheumatoid arthritis
39. Consistent improvement in radiographic joint damage in patients with active rheumatoid arthritis treated with infliximab along with methotrexate
40. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate and hemoglobin: Long-term course and the association to radiographic progression
41. Joint inflammation and cartilage destruction may occur uncoupled
42. Increased IL-1 receptor antagonist (IL-1 ra) production and decreased IL-1 beta/IL-1 ra ratio in mononuclear cells from rheumatoid arthritis patients
43. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils
44. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: Correlations with markers of inflammation and joint destruction
45. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate